Raiffeisen Bank International’s Sarepta Therapeutics SRPT Stock Holding History

Raiffeisen Bank International’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$970K	Buy	57,000 +5,000	+10%	+$94.6K	0.01%	418
2026 Q1	$1.06M	Buy	52,000 +2,000	+4%	+$38.7K	0.02%	380
2025 Q4	$1.07M	Buy	50,000 +5,000	+11%	+$105K	0.01%	339
2025 Q3	$847K	Buy	45,000 +3,535	+9%	+$63K	0.01%	355
2025 Q2	$723K	Buy	41,465 +24,000	+137%	+$1.02M	0.01%	317
2025 Q1	$1.22M	Buy	17,465 +16,000	+1,092%	+$1.68M	0.02%	255
2024 Q4	$176K	Buy	+1,465	New	+$180K	﹤0.01%	455

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Raiffeisen Bank International's SRPT Position: Q2 2026 in Review

Raiffeisen Bank International increased its Sarepta Therapeutics (SRPT) stake by 9.6% in Q2 2026, buying an estimated $94.6K and bringing the position to 57,000 shares worth $970K. The position accounts for 0.01% of the portfolio, ranked #418.

Raiffeisen Bank International first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.22M in Q1 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Raiffeisen Bank International held 57,000 shares of Sarepta Therapeutics worth $970K as of Q2 2026.
Raiffeisen Bank International bought 5,000 Sarepta Therapeutics shares in Q2 2026, an estimated $94.6K.
Sarepta Therapeutics made up 0.01% of Raiffeisen Bank International's portfolio in Q2 2026, its #418 holding.
Raiffeisen Bank International first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
Raiffeisen Bank International's Sarepta Therapeutics position peaked at $1.22M in Q1 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.